SCHEMBL25549042

SCHEMBL25549042

CC(c1ccccc1)[C@H](NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.61
GPR132 Q9UNW8 1/20 0.41
ADAMTS4 O75173 1/20 0.41
MMP13 P45452 1/20 0.41
MRGPRX4 Q96LA9 2/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
KIFC1 Q9BW19 1/20 0.39
PTGER4 P35408 1/20 0.38
PTGDR Q13258 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
ELANE P08246 1/20 0.38
DRD4 P21917 1/20 0.37
TACR1 P25103 1/20 0.37
CNR1 P21554 1/20 0.37
SENP5 Q96HI0 1/20 0.37
SENP2 Q9HC62 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461443 1.00 CXCR2 (0.61) CXCR2GPR132ADAMTS4MMP13MRGPRX4
SCHEMBL1598964 0.92 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL485430 0.92 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL23460682 0.91 CXCR2 (0.61) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL23460684 0.91 CXCR2 (0.61) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL23461572 0.90 CXCR2 (0.60) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL25549259 0.90 CXCR2 (0.60) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL23461571 0.90 CXCR2 (0.60) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL25549079 0.90 CXCR2 (0.62) CXCR2ADAMTS4MMP13MRGPRX4MME
SCHEMBL25192219 0.89 CXCR2 (0.64) CXCR2ADAMTS4MMP13MRGPRX4MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885GPR132 750/4885ADAMTS4 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.